Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis

September 16, 2022

CATEGORIES: Lupus Nephritis

First posted September 15, 2022, Updated September 15, 2022

This trial aims to learn about the safety and tolerability of daxdilimab (trial drug), and to learn about the effect it has on lupus nephritis when combined with standard treatment (that is, mycophenolate mofetil [MMF] or mycophenolic acid [MPA] and corticosteroids [also called steroids, which are a type of anti-inflammatory drugs]) when compared to combination of placebo and standard treatment.

To Learn More Contact

Call Horizon Therapeutics at 1-866-479-6742 or by email to identifier (NCT number): NCT05540665

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up